Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.01 – $0.15
5% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $101.5K | $755.2K | $1.8M | $718.3K | $1.0M | $2.1M |
| Cost of revenue | $0 | $156.3K | $64.2K | $55.4K | $407.1K | $345.9K | $457.0K | $905.1K |
| Gross profit | $0 | −$156.0K | $37.3K | $699.9K | $1.3M | $372.4K | $563.4K | $1.2M |
| Gross margin | — | — | 36.8% | 92.7% | 76.8% | 51.8% | 55.2% | 56.6% |
| R&D | $12.4K | $222.4K | $272.7K | $85.3K | $359.3K | $92.9K | $427.8K | $148.2K |
| Operating income | −$50.1K | −$11.5M | −$7.6M | −$1.8M | −$4.4M | −$3.8M | −$3.7M | $5.4M |
| EBITDA | −$50.1K | −$11.3M | −$7.4M | −$987.0K | −$7.6M | −$2.9M | −$3.0M | −$3.9M |
| Net income | −$50.1K | −$11.4M | −$8.0M | −$1.8M | −$8.5M | −$3.8M | −$4.3M | −$5.4M |
| Net margin | — | — | -7847.4% | -239.0% | -484.4% | -530.4% | -422.2% | -259.2% |
| EPS (diluted) | -0.05 | -0.18 | -0.10 | -0.03 | -0.08 | -0.04 | -0.04 | -0.04 |
Annual figures · source: Financial Modeling Prep
RAPID DOSE THERAPEUTICS
No one on the platform currently holds RDTCF.
No tracked institution reports a position in RDTCF as of their last filing.
No one on the platform has traded RDTCF yet.
| +24.39% |
| $11M |
| — |
| MNNDFNurosene Health Inc. | $0.33 | -8.71% | $14M | — |
| NOXOFNoxopharm Limited | $0.04 | +0.00% | $15M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.9× sales vs its 13.9× historical median P/S.
Fair value ≈ $0.21 · price $0.01 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.